Other Non-Current Liabilities
Pfizer Other Non-Current Liabilities decreased by 3.6% to $14.2B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.8%, from $13.3B to $14.2B. Over 5 years (FY 2020 to FY 2025), Other Non-Current Liabilities shows an upward trend with a 17.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
A significant increase may indicate new long-term commitments or legal contingencies, requiring further investigation into the nature of the underlying obligations.
Detailed definition
This includes long-term obligations that do not fall into specific categories like long-term debt or deferred taxes. Exa...
Peer comparison
Often contains idiosyncratic items; investors compare this to peer disclosures to identify hidden long-term risks or liabilities.
other_non_current_liabilitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $8.23B | $9.2B | $9.74B | $10.51B | $11.31B | $12.24B | $13.18B | $13.01B | $13.4B | $14.24B | $16.54B | $15.12B | $16.1B | $15.57B | $14.15B | $13.3B | $13.93B | $13.61B | $14.73B | $14.2B |
| QoQ Change | — | +11.8% | +5.9% | +7.9% | +7.6% | +8.2% | +7.7% | -1.3% | +3.0% | +6.3% | +16.1% | -8.6% | +6.4% | -3.3% | -9.1% | -6.0% | +4.8% | -2.3% | +8.2% | -3.6% |
| YoY Change | — | — | — | — | +37.5% | +33.0% | +35.3% | +23.8% | +18.5% | +16.4% | +25.5% | +16.2% | +20.1% | +9.3% | -14.4% | -12.1% | -13.4% | -12.6% | +4.1% | +6.8% |
Product Breakdown
| Segment | Q4 '22 | Q4 '23 | Q4 '25 |
|---|---|---|---|
| Paxlovid and Comirnaty | — | — | $826M |
| Comirnaty | $77M | — | — |
| Paxlovid | — | $1.9B | — |
| Total | $13.18B | $16.54B | $14.73B |
Paxlovid was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
Other Non-Current Liabilities at Other Companies
Frequently Asked Questions
- What is Pfizer's other non-current liabilities?
- Pfizer (PFE) reported other non-current liabilities of $14.2B in Q1 2026.
- How has Pfizer's other non-current liabilities changed year-over-year?
- Pfizer's other non-current liabilities increased by 6.8% year-over-year, from $13.3B to $14.2B.
- What is the long-term trend for Pfizer's other non-current liabilities?
- Over 5 years (2020 to 2025), Pfizer's other non-current liabilities has grown at a 17.2% compound annual growth rate (CAGR), from $6.67B to $14.73B.
- What does other non-current liabilities mean?
- Miscellaneous long-term debts that are not classified under standard categories.